Combining Immune Checkpoint and VEGFR Inhibition in Favorable Risk and Elderly Patients With Metastatic Renal Cell Carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Combining Immune Checkpoint and VEGFR Inhibition in Favorable Risk and Elderly Patients With Metastatic Renal Cell Carcinoma

Published:2020-06 Issue:3 Volume:18 Page:179-184.e3
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Varkaris Andreas^ORCID,Xu Wenxin,Davis Roger B.,Healy Brian,McDermott David F.

Funder

BMS

Prometheus Laboratories

Merck

Genentech

Pfizer

Exelixis

Novartis

X4 Pharma

Alkermes Inc

Peloton

Harvard Catalyst

The Harvard Clinical and Translational Science Center

National Center for Research Resources

National Center for Advancing Translational Sciences

National Institutes of Health

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference19 articles.

1. The changing therapeutic landscape of metastatic renal cancer;Angulo;Cancers (Basel),2019

2. Towards individualized therapy for metastatic renal cell carcinoma;Kotecha;Nat Rev Clin Oncol,2019

3. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma;Rini;N Engl J Med,2019

4. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma;Motzer;N Engl J Med,2019

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Brusatol improves the efficacy of an anti-mouse-PD-1 antibody via inhibiting programmed cell death 1 ligand 1 expression in a murine head and neck squamous cell carcinoma model;Archives of Oral Biology;2024-10

2. Association between neutrophil-to-eosinophil ratio and efficacy outcomes with avelumab plus axitinib or sunitinib in patients with advanced renal cell carcinoma: post hoc analyses from the JAVELIN Renal 101 trial;BMJ Oncology;2024-06

3. Small Bowel Perforation Due to Renal Carcinoma Metastasis: A Comprehensive Case Study and Literature Review;Diagnostics;2024-04-03

4. The Efficacy and Safety of Immune Checkpoint Inhibitor and Tyrosine Kinase Inhibitor Combination Therapy for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Real-World Cohort Study;Cancers;2023-02-02

5. First-line therapy for elderly patients with advanced renal cell carcinoma in the immuno-oncology era: a network meta-analysis;Cancer Immunology, Immunotherapy;2022-12-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3